Action 2185 SHANGHAI BIO-HEART BIOLOGICAL TECHNOLOGY CO., LTD.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Shanghai Bio-heart Biological Technology Co., Ltd.

Actions

2185

CNE100004JH3

Marché Fermé - Hong Kong S.E.
Autres places de cotation
 10:08:20 26/04/2024 		Varia. 5j. Varia. 1 janv.
2,02 HKD +3,59 % Graphique intraday de Shanghai Bio-heart Biological Technology Co., Ltd. +6,32 % -40,94 %
25/03 Shanghai Bio-heart Biological Technology Co. publie ses résultats pour l'exercice clos le 31 décembre 2023 CI
2023 Shanghai Bio-Heart Biological Technology Co. Ltd. annonce un changement de superviseur du représentant des employés annonce le changement de superviseur du représentant des employés CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Shanghai Bio-heart Biological Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Change of Employee Representative Supervisor
Shanghai Bio-heart Biological Technology's Loss Narrows in H1
Shanghai Bio-heart Biological Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Bioheart (02185.HK) announces clinical result for Iberis-HTN at CIT 2023
Bioheart Announces Clinical Result for Iberis-Htn At Cit 2023
Shanghai Bio-heart Biological Technology Co., Ltd. Announces Management Changes
Shanghai Bio-heart Injects 15 Million Yuan Into Medical Device Developer Xinzhi Medical; Shares Surge 17%
Shanghai Xinzhi Medical Technology Co., Ltd. announced that it expects to receive CNY 15 million in funding from Shanghai Bio-heart Biological Technology Co., Ltd.
Shanghai Bio-heart Biological Technology Achieves Primary Clinical Endpoint for Catheter System; Shares Climb 44%
Shanghai Bio-heart Biological Technology Co., Ltd. Announces Achievement of Primary Clinical Endpoint in the Iberis-HTN
Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Ji Chen Would Not Offer Himself for Re-Election as A Non-Executive Director
Shanghai Bio-heart Biological Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Shanghai Bio-heart Biological Technology Co., Ltd. Announces First Patient Enrollment in the RADIUS-HTN Trial
Shanghai Bio-heart Biological Technology Co., Ltd.(SEHK:2185) dropped from S&P Global BMI Index
Certain H Shares of Shanghai Bio-heart Biological Technology Co., Ltd. are subject to a Lock-Up Agreement Ending on 23-DEC-2022.
Shanghai Bio-heart to Conduct Clinical Trials in Japan for Restenosis Treatment
Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Clinical Trial of Sirolimus Drug-Eluting Balloon for the Treatment of In-Stent Restenosis
Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Its Iberis® multi-electrode RDN system product Approve by the Ethics Committee of Ruijin Hainan Hospital
Shanghai Bio-heart Biological Technology Gets Chinese Regulator’s Thumbs Up for H Shares
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 2185
  4. Actualités Shanghai Bio-heart Biological Technology Co., Ltd.
  5. Autres langues